Bigflex Lifescience Profile
Key Indicators
- Authorised Capital ₹ 9.50 Cr
as on 17-07-2024
- Paid Up Capital ₹ 8.60 Cr
as on 17-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -22.84%
(FY 2023)
- Profit 73.29%
(FY 2023)
- Ebitda 74.31%
(FY 2023)
- Net Worth 134.52%
(FY 2023)
- Total Assets -30.86%
(FY 2023)
About Bigflex Lifescience
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.50 Cr and a paid-up capital of Rs 8.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Adarsh Somani, Prashant Mantri, and Bal Gaggar serve as directors at the Company.
- CIN/LLPIN
U74999MH2019PTC322014
- Company No.
322014
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bigflex Lifescience Private Limited offer?
Bigflex Lifescience Private Limited offers a wide range of products and services, including Herbal Foods Beverages, Garcinia Cambogia, Herbal Extracts, Ashwagandha Extract, Me Pharm, Taurine.
Who are the key members and board of directors at Bigflex Lifescience?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Adarsh Somani  | Director | 28-Feb-2019 | Current |
| Prashant Mantri | Director | 07-Jul-2023 | Current |
| Bal Gaggar | Director | 28-Feb-2019 | Current |
Financial Performance and Corporate Structure Insights of Bigflex Lifescience.
Bigflex Lifescience Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.84% decrease. The company also saw a substantial improvement in profitability, with a 73.29% increase in profit. The company's net worth Soared by an impressive increase of 134.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bigflex Lifescience?
In 2023, Bigflex Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bigflex Lifescience?
Unlock and access historical data on people associated with Bigflex Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bigflex Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bigflex Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
